SCHEMBL1717020

SCHEMBL1717020

CCOC(=O)c1c(C)n(-c2ccccc2)c(=O)c2ccc(C)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
RECQL P46063 1/20 0.57
THRB P10828 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MAPT P10636 4/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
CHEK1 O14757 1/20 0.51
AURKA O14965 1/20 0.51
NTRK1 P04629 1/20 0.51
FYN P06241 1/20 0.51
MET P08581 1/20 0.51
PDGFRB P09619 1/20 0.51
PIM1 P11309 1/20 0.51
FGFR1 P11362 1/20 0.51
PDGFRA P16234 1/20 0.51
LTK P29376 1/20 0.51
GRK5 P34947 1/20 0.51
MAPK8 P45983 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1718672 0.95 MEN1 (0.62) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL1717720 0.89 RECQL (0.67) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL1717801 0.88 MEN1 (0.60) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL1717399 0.86 ALDH1A1 (0.57) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL1717043 0.85 MEN1 (0.56) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL1718271 0.84 GAA (0.57) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL2675778 0.83 MEN1 (0.60) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL1719451 0.83 MEN1 (0.60) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL1717992 0.83 MEN1 (0.60) MEN1KMT2ARECQLTHRBSMN1; SMN2
SCHEMBL4788204 0.81 RECQL (0.78) MEN1KMT2ARECQLTHRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MEN1 3960/4885KMT2A 1850/4885RECQL 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.